Abstract
In the current burgeoning biologic era of autoimmunity therapeutics, an expanding array of specific molecular targets are being used to dismantle the components of the dysregulated immune system felt to be responsible for tissue injury. We are learning that what works well for one disease may not
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Journal of the American Society of Nephrology : JASN
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
